Session

IBD: Clinical trials poster II

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY
BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN'S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU
LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN'S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU

VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE
VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE

VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES
VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL
PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL

EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN CROHN'S DISEASE PATIENTS WITH INSUFFICIENT RESPONSE TO STANDARD-DOSE SUBCUTANEOUS MAINTENANCE THERAPY: AN OBSERVATIONAL MULTICENTRE STUDY
EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN CROHN'S DISEASE PATIENTS WITH INSUFFICIENT RESPONSE TO STANDARD-DOSE SUBCUTANEOUS MAINTENANCE THERAPY: AN OBSERVATIONAL MULTICENTRE STUDY

PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL
PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL

IBD: Clinical trials poster II

LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN’S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU
LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN’S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU

IBD: Clinical trials poster II

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY
BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

IBD: Clinical trials poster II

VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE
VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE

IBD: Clinical trials poster II

EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN CROHN’S DISEASE PATIENTS WITH INSUFFICIENT RESPONSE TO STANDARD-DOSE SUBCUTANEOUS MAINTENANCE THERAPY: AN OBSERVATIONAL MULTICENTRE STUDY
EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN CROHN’S DISEASE PATIENTS WITH INSUFFICIENT RESPONSE TO STANDARD-DOSE SUBCUTANEOUS MAINTENANCE THERAPY: AN OBSERVATIONAL MULTICENTRE STUDY

IBD: Clinical trials poster II  et al.

PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL
PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL

IBD: Clinical trials poster II  et al.

VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES
VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

IBD: Clinical trials poster II  et al.

VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE
VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE

IBD: Clinical trials poster II  et al.

LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN’S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU
LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN’S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU

IBD: Clinical trials poster II  et al.

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY
BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

IBD: Clinical trials poster II  et al.

Item 1 - 16 / 16
1